Evoq remedies Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The submission, dated April 9, 2026, covers the quarter ended March 31, 2026.

Regulatory Compliance Certificate

The company submitted the confirmation certificate received from M/s. Accurate Securities & Registry Private Limited, its appointed Registrar and Share Transfer Agent (RTA), as mandated under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Certificate Confirmation Details

Accurate Securities & Registry Private Limited confirmed that all securities received from depository participants for dematerialisation during the reporting period were processed within the stipulated time limits specified under SEBI regulations. The processing included either acceptance or rejection on technical grounds as applicable.

The RTA further certified that:

• Securities comprised in the certificates have been listed on stock exchanges where earlier issued securities are listed
• Securities received for dematerialisation have been mutilated/cancelled after due verification
• Depository names have been substituted in the security holder's list as registered owners within regulatory time limits

Corporate Information

Evoq Remedies Limited operates from its registered office located at A-1106, Empire Business Hub Near AUDA Water Tank, Science City Road, Sola, Ahmedabad, Gujarat. The compliance certificate was signed by Managing Director Bhumishth Patel, who holds DIN: 02516641.

RTA Service Details

Accurate Securities & Registry Private Limited, registered with SEBI under registration number INR000004173, serves as the company's share transfer agent. The RTA operates from Monday to Friday with call hours from 11:30 AM to 5:00 PM, maintaining a lunch break from 1:30 PM to 2:30 PM.

This quarterly compliance submission demonstrates Evoq Remedies Limited's commitment to maintaining regulatory adherence and transparent reporting practices as required under SEBI guidelines for listed companies.

Evoq Remedies Limited has released its unaudited financial results for the half-year ended September 30, revealing a mixed performance amidst significant regulatory challenges and compliance issues.

Financial Performance

The company reported revenue from operations of ₹1,175.67 lakhs for the half-year, with a profit after tax of ₹5.43 lakhs. Total assets increased to ₹5,221.50 lakhs from ₹5,000.94 lakhs in March.

Key financial highlights:

Regulatory Challenges and Compliance Issues

Evoq Remedies faces several regulatory and compliance challenges:

1. SEBI Investigation: The company is under scrutiny from the Securities and Exchange Board of India (SEBI) regarding the preparation of its financial statements and the utilization of ₹9.21 crore raised through preferential allotment.

2. Audit Trail Software: The company has failed to implement mandatory audit trail software as required by the Companies Act, 2013.

3. GST Demand: An outstanding GST demand of ₹655.03 lakhs for the financial year 2017-18 is currently under litigation.

4. Income Tax Disputes: The company faces disputed income tax demands of ₹39.99 lakhs, which are not fully reflected in its accounts.

5. Unconfirmed Advances: Advances to suppliers amounting to ₹1,250.87 lakhs are subject to confirmation, raising concerns about their recoverability.

6. Related Party Transactions: The company has given loans totaling ₹668.86 lakhs to two related parties without adhering to relevant provisions of the Companies Act, 2013.

7. TDS and TCS Issues: The company has deducted/collected TDS and TCS amounting to ₹38.23 lakhs but has not paid it to the government.

Auditor's Concerns

The company's auditor, H Thakkar & Co. LLP, has raised several concerns in their limited review report, highlighting the regulatory issues and compliance failures mentioned above. The auditor has stated that they are unable to determine the financial impact of these issues on the company's financial position.

Management Response

Evoq Remedies' management has stated that they are in the process of responding to SEBI's summons and show cause notice. The company is also working on reconciling outstanding debtor balances and addressing the compliance issues raised by the auditor.

Company Overview

Evoq Remedies operates in agro commodity trading and has a paid-up share capital of ₹2,490 lakhs.

Outlook

While Evoq Remedies has shown some growth in total assets, the numerous regulatory challenges and compliance issues pose significant risks to the company's operations and financial stability. The company's ability to address these issues promptly and effectively will be crucial for maintaining investor confidence and ensuring long-term stability.